Europe’s presence among the world’s most valuable publicly traded companies has contracted sharply, with the continent now represented by only three stocks in the global top 50.
The latest shift sees Danish healthcare giant Novo Nordisk fall out of the elite group, accelerating a trend that has seen European representation drop from nine companies just three years ago.
The departure of a major European name from the top tier underscores the widening valuation gap between the continent and the US tech sector.
While American mega-caps continue to dominate global market capitalization, European equities face headwinds from slower growth expectations and a lack of comparable large-cap technology listings.
The reduction from nine to three slots in the top 50 highlights the increasing concentration of global market value in fewer regions.
This structural shift aligns with broader trends in cross-Atlantic capital flows.